JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On July28, 2017, the management team of Jaguar Animal Health,Inc. (“Jaguar”) hosted an investors’ call to announce the approval by shareholders of Jaguar and Napo Pharmaceuticals, Inc. (“Napo”) of the proposals recommended by the Jaguar and Napo boards regarding the previously announced merger between the two companies. On the call, Jaguar also provided updated guidance that Mytesi®, a first-in-class anti-secretory agent indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, is forecasted to generate approximately $7 million in revenue by April2018.
About JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX)
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over nine indications across various species and non-prescription products targeting approximately seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Virend, Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm. Canalevia is its lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm Calf and Neonorm Foal are its lead non-prescription products to improve gut health and normalize stool formation.